These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 12818727)

  • 1. Differential inhibition of human cytochrome P450 enzymes by epsilon-viniferin, the dimer of resveratrol: comparison with resveratrol and polyphenols from alcoholized beverages.
    Piver B; Berthou F; Dreano Y; Lucas D
    Life Sci; 2003 Jul; 73(9):1199-213. PubMed ID: 12818727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of CYP3A, CYP1A and CYP2E1 activities by resveratrol and other non volatile red wine components.
    Piver B; Berthou F; Dreano Y; Lucas D
    Toxicol Lett; 2001 Dec; 125(1-3):83-91. PubMed ID: 11701226
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potent inhibitory effect of alpha-viniferin on human cytochrome P450.
    Sim J; Jang HW; Song M; Kim JH; Lee SH; Lee S
    Food Chem Toxicol; 2014 Jul; 69():276-80. PubMed ID: 24769006
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal human lymphocytes.
    Billard C; Izard JC; Roman V; Kern C; Mathiot C; Mentz F; Kolb JP
    Leuk Lymphoma; 2002 Oct; 43(10):1991-2002. PubMed ID: 12481898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential inhibition and inactivation of human CYP1 enzymes by trans-resveratrol: evidence for mechanism-based inactivation of CYP1A2.
    Chang TK; Chen J; Lee WB
    J Pharmacol Exp Ther; 2001 Dec; 299(3):874-82. PubMed ID: 11714871
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol and its dimers ε-viniferin and δ-viniferin in red wine protect vascular endothelial cells by a similar mechanism with different potency and efficacy.
    Wu CW; Nakamoto Y; Hisatome T; Yoshida S; Miyazaki H
    Kaohsiung J Med Sci; 2020 Jul; 36(7):535-542. PubMed ID: 32118360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibition of human cytochrome P450 enzymes by the natural hepatotoxin safrole.
    Ueng YF; Hsieh CH; Don MJ
    Food Chem Toxicol; 2005 May; 43(5):707-12. PubMed ID: 15778010
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibitory effects of cytochrome P450 enzymes CYP1A2, CYP2A6, CYP2E1 and CYP3A4 by extracts and alkaloids of Gelsemium elegans roots.
    Wang Y; Wu S; Chen Z; Zhang H; Zhao W
    J Ethnopharmacol; 2015 May; 166():66-73. PubMed ID: 25764964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Resveratrol is a selective human cytochrome P450 1A1 inhibitor.
    Chun YJ; Kim MY; Guengerich FP
    Biochem Biophys Res Commun; 1999 Aug; 262(1):20-4. PubMed ID: 10448061
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro assessment of inhibition by natural polyphenols of metabolic activation of procarcinogens by human CYP1A1.
    Schwarz D; Roots I
    Biochem Biophys Res Commun; 2003 Apr; 303(3):902-7. PubMed ID: 12670496
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Greater effectiveness of ε-viniferin in red wine than its monomer resveratrol for inhibiting vascular smooth muscle cell proliferation and migration.
    Zghonda N; Yoshida S; Araki M; Kusunoki M; Mliki A; Ghorbel A; Miyazaki H
    Biosci Biotechnol Biochem; 2011; 75(7):1259-67. PubMed ID: 21737923
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Potent inhibition of cytochrome P450 2B6 by sibutramine in human liver microsomes.
    Bae SH; Kwon MJ; Choi EJ; Zheng YF; Yoon KD; Liu KH; Bae SK
    Chem Biol Interact; 2013 Sep; 205(1):11-9. PubMed ID: 23777987
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trans-resveratrol, but not other natural stilbenes occurring in food, carries the risk of drug-food interaction via inhibition of cytochrome P450 enzymes or interaction with xenosensor receptors.
    Hyrsova L; Vanduchova A; Dusek J; Smutny T; Carazo A; Maresova V; Trejtnar F; Barta P; Anzenbacher P; Dvorak Z; Pavek P
    Toxicol Lett; 2019 Jan; 300():81-91. PubMed ID: 30394306
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Differential Effects of Resveratrol and trans-ε-Viniferin on the GABA-Induced Current in GABAA Receptor Subtypes Expressed in Xenopus Laevis Oocytes.
    Groundwater PW; Hamid K; Ng I; Tallapragada VJ; Hibbs DE; Hanrahan J
    J Pharm Pharm Sci; 2015; 18(4):328-38. PubMed ID: 26626239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibitory effects of memantine on human cytochrome P450 activities: prediction of in vivo drug interactions.
    Micuda S; Mundlova L; Anzenbacherova E; Anzenbacher P; Chladek J; Fuksa L; Martinkova J
    Eur J Clin Pharmacol; 2004 Oct; 60(8):583-9. PubMed ID: 15378224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human liver cytochrome P450 by star fruit juice.
    Zhang JW; Liu Y; Cheng J; Li W; Ma H; Liu HT; Sun J; Wang LM; He YQ; Wang Y; Wang ZT; Yang L
    J Pharm Pharm Sci; 2007; 10(4):496-503. PubMed ID: 18261370
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4.
    Chan WK; Delucchi AB
    Life Sci; 2000 Nov; 67(25):3103-12. PubMed ID: 11125847
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Differential selectivity of cytochrome P450 inhibitors against probe substrates in human and rat liver microsomes.
    Eagling VA; Tjia JF; Back DJ
    Br J Clin Pharmacol; 1998 Feb; 45(2):107-14. PubMed ID: 9491822
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Liquid chromatography/tandem mass spectrometric determination of inhibition of human cytochrome P450 isozymes by resveratrol and resveratrol-3-sulfate.
    Yu C; Shin YG; Kosmeder JW; Pezzuto JM; van Breemen RB
    Rapid Commun Mass Spectrom; 2003; 17(4):307-13. PubMed ID: 12569440
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9).
    Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT
    Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.